GlassScriptPhysician profile
Sami M Ali
NPI 1821382250
$33,851.63
in general payments reported to CMS, 2019-2025
89 companies · $4,647 in 2025
The $4,647 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,626 · 2020: $2,665 · 2021: $5,088 · 2022: $5,248 · 2023: $7,081 · 2024: $6,496 · 2025: $4,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Long Term Medical Supply Or Device Loan: $2,250 · Consulting Fee: $656 · Education: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,750.40 |
| Long Term Medical Supply Or Device Loan | $2,249.91 |
| Consulting Fee | $655.50 |
| Education | $568.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,369.28 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,736.11 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $1,677.86 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,381.87 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Incyte Corporation | $1,355.16 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Bayer Healthcare Pharmaceuticals INC. | $1,282.36 | 2019-2025 | |
| Janssen Biotech, INC. | $1,240.26 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $1,161.36 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $1,110.12 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Astrazeneca Pharmaceuticals LP | $1,094.97 | 2019-2025 | Lynparza, Tagrisso, Calquence |
| Seagen INC. | $926.45 | 2019-2023 | Adcetris, Tivdak, Padcev |
| Astellas Pharma US INC | $925.32 | 2019-2025 | Xtandi, Xospata, Vyloy |
| Exelixis INC. | $898.15 | 2019-2025 | Cabometyx |
| Celgene Corporation | $793.01 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $771.61 | 2022-2025 | Enhertu, Datroway |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $748.76 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Lilly USA, LLC | $705.04 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $652.52 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Eisai INC. | $564.43 | 2019-2025 | |
| Gilead Sciences, INC. | $552.13 | 2019-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $529.51 | 2020-2023 | Imbruvica |
| Genentech USA, INC. | $484.68 | 2019-2025 | Polivy, Venclexta, Phesgo |
| Genzyme Corporation | $462.87 | 2019-2025 | |
| Abbvie INC. | $405.28 | 2023-2025 | Venclexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.70 | 2019-2025 | Gilotrif |
| Karyopharm Therapeutics INC. | $316.44 | 2021-2025 | Xpovio |
| Taiho Oncology, INC. | $308.37 | 2019-2024 | |
| Blueprint Medicines Corporation | $272.58 | 2020-2024 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $236.28 | 2021-2025 | Libtayo, Lynozyfic |
| Emd Serono, INC. | $235.70 | 2020-2025 | Bavencio |
| Pharmaessentia USA Corporation | $208.05 | 2022-2025 | Besremi |
| Dendreon Pharmaceuticals LLC | $206.32 | 2020-2022 | |
| Kite Pharma, INC. | $201.54 | 2021-2023 | |
| Rigel Pharmaceuticals, INC. | $197.81 | 2019-2023 | Tavalisse, Rezlidhia |
| Stemline Therapeutics INC. | $181.10 | 2023-2025 | Orserdu, Elzonris |
| Agios Pharmaceuticals, INC. | $174.30 | 2019-2025 | Pyrukynd |
| Tolmar Pharmaceuticals, INC. | $170.31 | 2019-2022 | |
| Dova Pharmaceuticals | $166.30 | 2019-2021 | |
| Sobi, INC | $159.20 | 2022-2025 | |
| Array Biopharma INC | $154.59 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Puma Biotechnology, INC. | $153.08 | 2019-2025 | |
| Genmab U.S., INC. | $146.64 | 2024-2025 | Epkinly |
| Emmaus Medical, INC. | $130.24 | 2019-2024 | Endari |
| Jazz Pharmaceuticals INC. | $114.33 | 2019-2025 | Zepzelca |
| Alexion Pharmaceuticals, INC. | $113.33 | 2019-2024 | Ultomiris |
| Myovant Sciences INC. | $105.58 | 2021-2022 | |
| Morphosys, US INC. | $102.66 | 2022-2023 | Monjuvi |
| Mirati Therapeutics, INC. | $101.76 | 2023-2024 | Krazati |
| Novocure INC. | $92.61 | 2019-2024 | Optune |
| Clovis Oncology, INC. | $92.01 | 2019 | |
| Global Blood Therapeutics, INC. | $83.78 | 2020-2022 | |
| Immunogen, INC. | $75.09 | 2023 | Elahere |
| Deciphera Pharmaceuticals INC. | $70.76 | 2020-2025 | Qinlock, Romvimza |
| Progenics Pharmaceuticals, INC. | $69.56 | 2023-2025 | Pylarify |
| Secura Bio, INC. | $67.61 | 2019-2023 | Copiktra |
| Epizyme, INC. | $66.72 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $57.97 | 2024-2025 | Danziten, Vivimusta |
| Aveo Pharmaceuticals, INC. | $53.39 | 2023-2025 | Fotivda |
| Sun Pharmaceutical Industries INC. | $51.79 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $49.89 | 2021-2022 | |
| Ge Healthcare | $45.39 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $44.45 | 2019-2020 | |
| Blue Earth Diagnostics | $44.28 | 2022 | |
| Coherus Oncology, INC. | $42.71 | 2024 | |
| Eusa Pharma (US) LLC | $41.74 | 2021-2022 | |
| Adc Therapeutics America, INC. | $40.96 | 2024 | |
| Tolmar, INC. | $37.75 | 2023-2024 | |
| Tersera Therapeutics LLC | $33.72 | 2019 | |
| Janssen Scientific Affairs, LLC | $29.29 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $28.85 | 2025 | Neffy |
| Amneal Pharmaceuticals LLC | $27.89 | 2023 | Neulasta, Neupogen, Avastin |
| Foundation Medicine, INC. | $26.89 | 2023 | Foundationone Liquid Cdx |
| Catalyst Pharmaceuticals, INC. | $26.23 | 2023 | Firdapse |
| Syndax Pharmaceuticals, INC. | $25.87 | 2025 | |
| Verastem, INC. | $24.84 | 2019 | |
| Beone Medicines USA, INC. | $24.83 | 2025 | Brukinsa |
| Mylan Institutional INC. | $23.61 | 2022 | |
| Springworks Therapeutics, INC. | $22.87 | 2025 | Ogsiveo |
| Legend Biotech USA INC. | $22.46 | 2025 | Carvykti |
| Tesaro, INC. | $20.15 | 2019 | |
| Boston Scientific Corporation | $18.95 | 2023 | Bodyguardian |
| G1 Therapeutics, INC. | $18.40 | 2023 | Cosela |
| Innate Pharma, INC | $16.06 | 2020 | |
| Sirtex Medical INC | $14.94 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$250.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.